Eisai opens sales, marketing operation in Netherlands

Eisai‘s sales and marketing operation will initially market epilepsy treatment drug Zonegran (zonisamide) in the Netherlands.

Eisai Netherlands managing director Gert-Jan Kouseband said Eisai’s entry into the country is aligned with the company’s wider strategy of establishing a solid foundation in Europe.

"We currently have one product on the market and hope to have five products available in the coming months, boosting our presence in the market," Kouseband said.

"This will allow Dutch patients access to treatments not previously available to them and further supports Eisai’s human health care (hhc) mission to satisfy unmet medical needs and contribute to the health and well being of people worldwide."